End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
32.77 CNY | +0.06% | +4.03% | -20.96% |
25/04 | Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
18/04 | Huadong Medicine's 2023 Profit Jumps 14% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-20.96% | 7.91B | B- | ||
+17.35% | 71.39B | C+ | ||
+2.39% | 25.1B | C+ | ||
+5.38% | 8.59B | C | ||
+6.69% | 8.19B | B | ||
+0.49% | 4.54B | B- | ||
+17.12% | 4.31B | B+ | ||
-2.61% | 3.86B | B | ||
+22.08% | 3.64B | C+ | ||
+7.96% | 3.29B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000963 Stock
- Ratings Huadong Medicine Co., Ltd